<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28371461</article-id><article-id pub-id-type="pmc">5754533</article-id><article-id pub-id-type="doi">10.1111/jdi.12661</article-id><article-id pub-id-type="publisher-id">JDI12661</article-id><article-categories><subj-group subj-group-type="overline"><subject>Clinical Trial</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Science and Care</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/<styled-content style="fixed-case">mL</styled-content> vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study</article-title><alt-title alt-title-type="left-running-head">Takeishi <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12661-cr-0001" contrib-type="author" corresp="yes"><name><surname>Takeishi</surname><given-names>Soichi</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4181-986X</contrib-id><address><email>souichi19811225@yahoo.co.jp</email></address><xref ref-type="aff" rid="jdi12661-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdi12661-cr-0002" contrib-type="author"><name><surname>Tsuboi</surname><given-names>Hiroki</given-names></name><xref ref-type="aff" rid="jdi12661-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdi12661-cr-0003" contrib-type="author"><name><surname>Takekoshi</surname><given-names>Shodo</given-names></name><xref ref-type="aff" rid="jdi12661-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jdi12661-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Diabetes</named-content>
<institution>General Inuyamachuo Hospital</institution>
<named-content content-type="city">Inuyama&#x02010;city</named-content>
<named-content content-type="country-part">Aichi</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Soichi Takeishi<break/>
Tel.: +81&#x02010;568&#x02010;62&#x02010;8111<break/>
Fax: +81&#x02010;568&#x02010;62&#x02010;9289<break/>
E&#x02010;mail address: <email>souichi19811225@yahoo.co.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2018</year></pub-date><volume>9</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/jdi.2018.9.issue-1</issue-id><fpage>91</fpage><lpage>99</lpage><history><date date-type="received"><day>30</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>13</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 Asian Association for the Study of Diabetes and John Wiley & Sons Australia, Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &#x00026; Sons Australia, Ltd</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDI-9-91.pdf"/><abstract id="jdi12661-abs-0001"><title>Abstract</title><sec id="jdi12661-sec-0001"><title>Introduction</title><p>We compared the effects of morning administration of insulin glulisine + insulin glargine 300 U/<styled-content style="fixed-case">mL</styled-content> (G + G300) with that of insulin lispro + insulin glargine biosimilar (L + <styled-content style="fixed-case">GB</styled-content>).</p></sec><sec id="jdi12661-sec-0002"><title>Materials and Methods</title><p>A total of 30 patients with type 2 diabetes who wore a continuous glucose monitoring device on admission after glucose levels were stabilized by morning long&#x02010;acting and ultra&#x02010;rapid&#x02010;acting insulins were randomly allocated to groups who received G + G300 on days 1 and 2, and the same dose L + <styled-content style="fixed-case">GB</styled-content> on days 3 and 4, or vice versa. Data collected on days 2 and 4 (mean amplitude of glycemic excursion, mean of daily differences: all days) were analyzed. Insulin was injected at 08.00 h. A day was defined as the period from 08.00 h one day, to 08.00 h the next day. Test meals were given.</p></sec><sec id="jdi12661-sec-0003"><title>Results</title><p>Increased post&#x02010;breakfast glucose level, post&#x02010;breakfast glucose gradient, mean glucose level, standard deviation and M&#x02010;value (24 h, 00.00&#x02013;06.00 h), mean amplitude of glycemic excursion, and mean of daily differences were significantly lower in patients taking G + G300 than those taking L + <styled-content style="fixed-case">GB</styled-content> (<italic>P</italic> &#x02264; 0.0001&#x02013;0.04). The area over the glucose curve (&#x0003c;70 mg/<styled-content style="fixed-case">dL</styled-content>) was not significantly different between groups. Pre&#x02010;lunch &#x02212; pre&#x02010;breakfast glucose levels were significantly lower in patients taking L + <styled-content style="fixed-case">GB</styled-content> than those taking G + G300 (<italic>P</italic> &#x0003c; 0.0001). The difference in the highest post&#x02010;breakfast glucose level between groups (&#x00394; = G + G300 &#x02212; L + <styled-content style="fixed-case">GB</styled-content>) was significantly correlated to 24&#x02010;h mean glucose level (<italic>r</italic> = 0.40, <italic>P</italic> = 0.03).</p></sec><sec id="jdi12661-sec-0004"><title>Conclusions</title><p>Compared with L + <styled-content style="fixed-case">GB</styled-content>, G + G300 decreases post&#x02010;breakfast glucose level reducing rate of rise of that, nocturnal and 24&#x02010;h glucose variability and level without causing hypoglycemia, and daily variance.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jdi12661-kwd-0001">Continuous glucose monitoring</kwd><kwd id="jdi12661-kwd-0002">Long&#x02010;acting insulin</kwd><kwd id="jdi12661-kwd-0003">Ultra&#x02010;rapid&#x02010;acting insulin</kwd></kwd-group><funding-group><award-group><funding-source>General Inuyamachuo Hospital</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="9"/><word-count count="6467"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12661</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.8 mode:remove_FC converted:05.01.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jdi12661-cit-1001">
<source>J Diabetes Investig</source>
<year>2018</year>; <volume>9</volume>: <fpage>91</fpage>&#x02013;<lpage>99</lpage>
</mixed-citation>
</p><fn-group id="jdi12661-ntgp-0001"><fn id="jdi12661-note-1001"><p>
<bold>Clinical Trial Registry</bold>
</p><p>
<italic>University Medical Information Network</italic>
</p><p>UMIN000022094</p></fn></fn-group></notes></front><body><sec id="jdi12661-sec-0005"><title>Introduction</title><p>A relationship between nocturnal hypoglycemia and sudden death has been suggested.<xref rid="jdi12661-bib-0001" ref-type="ref">1</xref> As per the Somogyi phenomenon, nocturnal hypoglycemia causes an increase in the difference between pre&#x02010; and post&#x02010;breakfast glucose levels.<xref rid="jdi12661-bib-0002" ref-type="ref">2</xref> Thus, hypoglycemia and increased glycemic variability occur at the same time in the Somogyi phenomenon. Large clinical studies have shown that hypoglycemia and glycemic variability are associated with mortality in patients with diabetes mellitus.<xref rid="jdi12661-bib-0003" ref-type="ref">3</xref>, <xref rid="jdi12661-bib-0004" ref-type="ref">4</xref>, <xref rid="jdi12661-bib-0005" ref-type="ref">5</xref> We wanted to predict the Somogyi phenomenon, in which hypoglycemia and increased glycemic variability occur concomitantly, and we have reported that major increases between pre&#x02010; and post&#x02010;breakfast glucose levels might predict nocturnal hypoglycemia in type 2 diabetes patients.<xref rid="jdi12661-bib-0006" ref-type="ref">6</xref>
</p><p>When the Somogyi phenomenon is suspected, reducing both nocturnal hypoglycemia and increases between pre&#x02010; and post&#x02010;breakfast glucose levels, and controlling pre&#x02010;breakfast glucose levels properly, is necessary.<xref rid="jdi12661-bib-0001" ref-type="ref">1</xref>, <xref rid="jdi12661-bib-0004" ref-type="ref">4</xref>, <xref rid="jdi12661-bib-0007" ref-type="ref">7</xref> We consider that morning long&#x02010;acting insulin reducing nocturnal hypoglycemia and ultra&#x02010;rapid&#x02010;acting insulin reducing increases between pre&#x02010; and post&#x02010;breakfast glucose levels accurately are useful. Adding one ultra&#x02010;rapid&#x02010;acting insulin to long&#x02010;acting insulin is recommended in the American Diabetes Association's guideline.<xref rid="jdi12661-bib-0008" ref-type="ref">8</xref> Therefore, this treatment is thought to be useful as an insulin therapy that is injected in the morning only.</p><p>Regarding reducing nocturnal hypoglycemia, nocturnal and overall hypoglycemia were significantly reduced in patients taking insulin glargine 300 U/mL (glargine 300 U/mL), as opposed to insulin glargine 100 U/mL (glargine 100 U/mL) in the Every Day in the Life of Patients with Diabetes Japan 2 trial.<xref rid="jdi12661-bib-0009" ref-type="ref">9</xref> Therefore, glargine 300 U/mL is thought to be useful as a long&#x02010;acting insulin in reducing nocturnal hypoglycemia.</p><p>Regarding increases between pre&#x02010; and post&#x02010;breakfast glucose levels, post&#x02010;breakfast glucose levels are often increased to a greater extent than post&#x02010;lunch or post&#x02010;supper glucose levels, and can cause increased glycemic variability over 24 h.<xref rid="jdi12661-bib-0010" ref-type="ref">10</xref> The glucose level after the first meal (breakfast),<xref rid="jdi12661-bib-0011" ref-type="ref">11</xref> and sometimes the Somogyi phenomenon<xref rid="jdi12661-bib-0002" ref-type="ref">2</xref> and the dawn phenomenon,<xref rid="jdi12661-bib-0012" ref-type="ref">12</xref> are the main causes of increased morning glucose levels. However, the Somogyi phenomenon is mainly caused by nocturnal hypoglycemia. Differentiating the Somogyi phenomenon from the dawn phenomenon is difficult, unless whether nocturnal hypoglycemia is occurring or not is known. In any case the following are necessary in order to reduce increases in post&#x02010;breakfast glucose levels: (i) adjusting treatment to avoid nocturnal hypoglycemia when nocturnal hypoglycemia causes increased morning glucose levels; and (ii) decreasing post&#x02010;breakfast glucose levels directly by adjusting treatment. Regarding (ii), knowledge of a patient's morning glycemic variability status is important for improving increased glycemic variability over 24 h. We focused on using patient characteristics to predict morning glycemic variability, and we have reported the relationship between patient characteristics and morning glycemic variability in a previous study.<xref rid="jdi12661-bib-0013" ref-type="ref">13</xref> In that study, higher age and lower body mass index (BMI) were observed to be associated with higher highest increased post&#x02010;breakfast glucose levels. Furthermore, longer durations of diabetes and lower BMI were correlated with a higher post&#x02010;breakfast glucose gradient. Therefore, we believe that treatments that decrease post&#x02010;breakfast glucose levels in elderly diabetes patients, as well as a delay or reduction in the increases in post&#x02010;breakfast glucose levels of diabetes patients with low BMI values, should be considered. Specifically, we believe that insulin glulisine (glulisine), which has a fast onset of action, is beneficial in this clinical scenario. It has been reported that switching to glulisine from another ultra&#x02010;rapid&#x02010;acting insulin with almost the same dose improved postprandial glucose levels and glycosylated hemoglobin levels.<xref rid="jdi12661-bib-0014" ref-type="ref">14</xref> Therefore, we hypothesized that glulisine is useful as the ultra&#x02010;rapid&#x02010;acting insulin in reducing increases between pre&#x02010; and post&#x02010;breakfast glucose levels.</p><p>Thus, a combination therapy of glargine 300 U/mL (considered to reduce nocturnal hypoglycemia and pre&#x02010;breakfast glucose levels) and glulisine (post&#x02010;breakfast glucose level, the rate of rise of which was reduced, decreases, because the effects of the difference of insulin concentration on glulisine were faster and stronger) administered in the morning might be beneficial. We compared the effects of morning administration of insulin glulisine + insulin glargine 300 U/mL (G + G300) with that of insulin lispro + insulin glargine biosimilar (L + GB) using continuous glucose monitoring (CGM) in a randomized cross&#x02010;over study.</p></sec><sec id="jdi12661-sec-0006"><title>Methods</title><sec id="jdi12661-sec-0007"><title>Study design and patient selection</title><p>Fasting plasma glucose (FPG) of the glargine 100 U/mL group in the Every Day in the Life of Patients with Diabetes Japan 2 trial<xref rid="jdi12661-bib-0009" ref-type="ref">9</xref> was 133.84 &#x000b1; 34.73 mg/dL. The number of individuals for whom a 30% alteration of the mean FPG could be detected with an &#x003b1; value of 0.05 and with a statistical power of 80% was 13. We assumed that 10% of those recruited might drop out of the trial, and therefore determined the total number of participants required to be 15. The glucose level of the insulin lispro (lispro) group of patients with type 2 diabetes in the clinical trial investigating efficacy and safety of glulisine reported by Morishita<xref rid="jdi12661-bib-0015" ref-type="ref">15</xref> was 162.51 &#x000b1; 58.94 mg/dL, 1 h post&#x02010;breakfast. The number of individuals for whom a 30% alteration of the mean 1&#x02010;h post&#x02010;breakfast glucose level could be detected with an &#x003b1; value of 0.05 and with a statistical power of 80% was 24. We assumed that 10% of those recruited might drop out of the trial, and therefore determined the total number of participants required to be 27. From the above, the necessary number of samples was determined to be 27.</p><p>A total of 30 patients with type 2 diabetes treated with basal insulin for 3 months or longer were investigated. The patients who wore a CGM device (Medtronic ipro2; Medtronic Minimed, Northridge, CA, USA) on admission were randomly allocated to separate groups (each group included 15 patients) who received G + G300 on days 1 and 2, and the same dose of L + GB on days 3 and 4, or who received L + GB on days 1 and 2, and the same dose of G + G300 on days 3 and 4.<xref rid="jdi12661-bib-0016" ref-type="ref">16</xref> Patients were allocated to groups using a random number table, and the study design was continuous and prospective. When basal insulin was insulin degludec, it was changed to another long&#x02010;acting insulin after enrollment. All patients&#x02019; insulin regimens were unified into morning long&#x02010;acting insulin and ultra&#x02010;rapid&#x02010;acting insulin after enrollment. Insulin was titrated to stabilize FPG not exceeding 180 mg/dL for 3 days, and then the CGM device was attached. Glucose levels were measured for four consecutive days by the CGM device, and data collected on days 2 and 4 (mean amplitude of glycemic excursion [MAGE],<xref rid="jdi12661-bib-0017" ref-type="ref">17</xref> mean of daily differences [MODD]<xref rid="jdi12661-bib-0018" ref-type="ref">18</xref> and average daily risk range<xref rid="jdi12661-bib-0019" ref-type="ref">19</xref>: days 1 and 2, and days 3 and 4) were analyzed. Insulin was injected at 08.00 h. A day was defined as the period from 08.00 h 1 day, to 08.00 h the next day. Regarding other diabetes treatments, &#x003b1;&#x02010;glucosidase inhibitors, rapid&#x02010;acting insulin secretagogues and glucagon&#x02010;like peptide&#x02010;1 receptor agonists were discontinued after enrollment. All other treatments were continued during the CGM measurement period. The participants received test meals consisting of the same nutrients and equivalent caloric intake during the CGM measurement period. The total caloric intake for participants was defined by the attending physicians, as 1,440 kcal, 1,600 kcal or 1,840 kcal per day to accommodate differences in physique among the participants.<xref rid="jdi12661-bib-0020" ref-type="ref">20</xref> Test meals were given to each patient based on the recommendation of the Japan Diabetes Society (component ratio of calories [carbohydrates 60%, proteins 18% and lipids 22%; breakfast 30%; lunch 35%; supper 35%]), irrespective of differences in physique during the CGM measurement period. Physical activity at admission to the study was 1.5 metabolic equivalents based on the analysis of baseline data. Patients with severe renal dysfunction (serum creatinine level &#x02265;2.0 mg/dL) or judged to be unsuitable for participation for medical reasons were excluded from this study.</p><p>The study protocol was approved by the ethical committee of General Inuyamachuo Hospital (authorization no. I, 2016), and was registered in a clinical trial database with the University Medical Information Network (no. UMIN000022094).</p></sec><sec id="jdi12661-sec-0008"><title>Statistical analysis</title><p>The CGM end&#x02010;point included M&#x02010;value (24 h [target glucose level 100], 08.00&#x02013;12.00 h [target glucose level = 120], 12.00&#x02013;24.00 h [target glucose level 120], 00.00&#x02013;06.00 h [target glucose level 90]),<xref rid="jdi12661-bib-0021" ref-type="ref">21</xref> MAGE (MAGE of increased glucose levels [MAGE+], MAGE of decreased glucose levels [MAGE&#x02212;]),<xref rid="jdi12661-bib-0017" ref-type="ref">17</xref> MODD, average daily risk range, mean glucose level (24 h, 08.00&#x02013;12.00 h, 12.00&#x02013;24.00 h, 00.00&#x02013;06.00 h), standard deviation (SD)<xref rid="jdi12661-bib-0022" ref-type="ref">22</xref> (24 h, 08.00&#x02013;12.00 h, 12.00&#x02013;24.00 h, 00.00&#x02013;06.00 h), preprandial glucose level (lunch &#x02212; breakfast),<xref rid="jdi12661-bib-0023" ref-type="ref">23</xref> highest postprandial glucose level within 3 h after each meal (highest glucose level), time from start of meal to the highest postprandial glucose level (highest glucose time), difference between preprandial and highest postprandial glucose level for each meal (increased glucose level), postprandial glucose gradient, area under the glucose curve (AUC; &#x02265;180 mg/dL) within 3 h of each meal, AUC (&#x02265;0 mg/dL) in 24 h and area over the glucose curve (AOC; &#x0003c;70 mg/dL) (24 h, 08.00&#x02013;12.00 h, 00.00&#x02013;06.00 h).<xref rid="jdi12661-bib-0024" ref-type="ref">24</xref>
</p><p>Data are shown as median (interquartile range). Statistical analysis was carried out with Wilcoxon signed&#x02010;rank test. A <italic>P</italic>&#x02010;value of &#x0003c;0.05 was considered significant.</p></sec></sec><sec id="jdi12661-sec-0009"><title>Results</title><sec id="jdi12661-sec-0010"><title>Patient characteristics</title><p>Table <xref rid="jdi12661-tbl-0001" ref-type="table-wrap">1</xref> shows the patients&#x02019; characteristics. The study included 13 men and 17 women. The baseline characteristics were as follows: age, 71.5 years (65.0&#x02013;80.0 years); duration of diabetes, 15.0 years (10.0&#x02013;20.0 years); BMI, 25.3 kg/m<sup>2</sup> (22.4&#x02013;26.7 kg/m<sup>2</sup>); glycosylated hemoglobin, 8.3% (7.6&#x02013;9.3%); C&#x02010;peptide immunoreactivity, 1.2 ng/mL (0.8&#x02013;1.7 ng/mL); FPG level, 140.5 mg/dL (111.8&#x02013;190.0 mg/dL); C&#x02010;peptide index, 0.7 (0.6&#x02013;1.1); urine C&#x02010;peptide immunoreactivity, 23.4 &#x003bc;g/day (12.5&#x02013;48.9 &#x003bc;g/day); basal insulin dose, 12.0 U/day (8.0&#x02013;24.0 U/day); bolus insulin dose, 6.0 U/day (4.0&#x02013;7.5 U/day); total insulin dose, 18.0 U/day (14.0&#x02013;30.0 U/day); and basal/total insulin dose ratio 70.3% (62.5&#x02013;75.0%; Table <xref rid="jdi12661-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="jdi12661-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="char" valign="top" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic> (male/female)</td><td align="char" char=" " rowspan="1" colspan="1">30 (13/17)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char=" " rowspan="1" colspan="1">71.5 (65.0&#x02013;80.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of diabetes (years)</td><td align="char" char=" " rowspan="1" colspan="1">15.0 (10.0&#x02013;20.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" char=" " rowspan="1" colspan="1">25.3 (22.4&#x02013;26.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c, NGSP (%)</td><td align="char" char=" " rowspan="1" colspan="1">8.3 (7.6&#x02013;9.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">GA (%)</td><td align="char" char=" " rowspan="1" colspan="1">21.8 (19.2&#x02013;24.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">CPR (ng/mL)</td><td align="char" char=" " rowspan="1" colspan="1">1.2 (0.8&#x02013;1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">140.5 (111.8&#x02013;190.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">CPI</td><td align="char" char=" " rowspan="1" colspan="1">0.7 (0.6&#x02013;1.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">U&#x02010;CPR (&#x003bc;g/day)</td><td align="char" char=" " rowspan="1" colspan="1">23.4 (12.5&#x02013;48.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Basal insulin dose (U/day)</td><td align="char" char=" " rowspan="1" colspan="1">12.0 (8.0&#x02013;24.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bolus insulin dose (U/day)</td><td align="char" char=" " rowspan="1" colspan="1">6.0 (4.0&#x02013;7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total insulin dose (U/day)</td><td align="char" char=" " rowspan="1" colspan="1">18.0 (14.0&#x02013;30.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Basal/Total insulin dose ratio (%)</td><td align="char" char=" " rowspan="1" colspan="1">70.3 (62.5&#x02013;75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sulfonylurea agent, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Biguanide agent, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">19 (63.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Thiazolidine, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">DPP4 inhibitor, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">21 (70.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">SGLT 2 inhibitor, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">8 (26.7)</td></tr></tbody></table><table-wrap-foot><fn id="jdi12661-note-0002"><p>Data are shown as median (interquartile range). BMI, body mass index; CPI, C&#x02010;peptide index; CPR, C&#x02010;peptide immunoreactivity; DPP, dipeptidyl&#x02010;peptidase; FPG, fasting plasma glucose; GA, glycoalbumin; HbA1c, glycosylated hemoglobin; SGLT, sodium glucose co&#x02010;transporter; U&#x02010;CPR, urine C&#x02010;peptide immunoreactivity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jdi12661-sec-0011"><title>Primary outcomes</title><p>Figure <xref rid="jdi12661-fig-0001" ref-type="fig">1</xref> shows the glycemic variability over 24 h of CGM in all of the patients.</p><fig fig-type="Figure" xml:lang="en" id="jdi12661-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The graph shows glucose variability over 24 h on continuous glucose monitoring (CGM) in patients during treatment with insulin glulisine + insulin glargine 300 U/mL (G + G300) or insulin lispro + insulin glargine biosimilar (L + GB). Glucose levels were calculated from the value of CGM on the second day after the start of each therapy. Data are shown as median (thick lines) and interquartile ranges (fine lines).</p></caption><graphic id="nlm-graphic-3" xlink:href="JDI-9-91-g001"/></fig><p>The M&#x02010;values (24 h, 00.00&#x02013;06.00 h, 08.00&#x02013;12.00 h) were significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.003, <italic>P</italic> = 0.0004, <italic>P</italic> = 0.04, respectively). MAGE, MAGE+ and MAGE&#x02212; were significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.0001, <italic>P</italic> &#x0003c; 0.0001, <italic>P</italic> = 0.0004, respectively). MODD was significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.004). Mean glucose levels (24 h, 00.00&#x02013;06.00 h, 12.00&#x02013;24.00 h) were significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.0002, <italic>P</italic> = 0.0002, <italic>P</italic> = 0.01, respectively). SDs (24 h, 00.00&#x02013;06.00 h, 08.00&#x02013;12.00 h) were significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.008, <italic>P</italic> = 0.0003, <italic>P</italic> = 0.009, respectively). Pre&#x02010;lunch &#x02212; pre&#x02010;breakfast glucose level was significantly lower in patients taking L + GB than those taking G + G300 (<italic>P</italic> &#x02264; 0.0001). The highest post&#x02010;breakfast glucose level was significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> &#x02264; 0.0001). Increased post&#x02010;breakfast glucose level was significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.0001). The post&#x02010;breakfast glucose gradient was significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.0007). AUC (&#x02265;180 mg/dL) within 3 h after breakfast was significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.001). The AUC (&#x02265;0 mg/dL) in 24 h was significantly lower in patients taking G + G300 than those taking L + GB (<italic>P</italic> = 0.0002). The area over the glucose curve (&#x0003c;70 mg/dL) was not significantly different between groups (Table <xref rid="jdi12661-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jdi12661-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Parameters of glucose variability in patients treated with insulin glulisine + insulin glargine 300 U/mL or insulin lispro + insulin glargine biosimilar</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="char" valign="top" rowspan="1" colspan="1">Glulisine + glargine 300 U/mL</th><th align="char" valign="top" rowspan="1" colspan="1">Lispro + glargine biosimilar</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">24&#x02010;h M&#x02010;value (target glucose level 100 mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">8.4 (4.4&#x02013;22.4)</td><td align="char" char=" " rowspan="1" colspan="1">9.7 (6.2&#x02013;31.9)</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">00.00&#x02013;06.00 h M&#x02010;value (target glucose level 90 mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">1.5 (0.4&#x02013;11.2)</td><td align="char" char=" " rowspan="1" colspan="1">5.1 (1.7&#x02013;22.4)</td><td align="char" char="." rowspan="1" colspan="1">0.0004</td></tr><tr><td align="left" rowspan="1" colspan="1">08.00&#x02013;12.00 h M&#x02010;value (target glucose level 120 mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">2.1 (0.7&#x02013;5.9)</td><td align="char" char=" " rowspan="1" colspan="1">2.6 (1.2&#x02013;7.4)</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">12.00&#x02013;24.00 h M&#x02010;value (target glucose level 120 mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">4.6 (2.4&#x02013;14.9)</td><td align="char" char=" " rowspan="1" colspan="1">4.7 (2.7&#x02013;22.5)</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">MAGE (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">47.6 (38.2&#x02013;55.7)</td><td align="char" char=" " rowspan="1" colspan="1">53.2 (46.1&#x02013;86.8)</td><td align="char" char="." rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">MAGE of increased glucose levels (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">48.3 (38.9&#x02013;56.9)</td><td align="char" char=" " rowspan="1" colspan="1">54.1 (47.4&#x02013;86.9)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">MAGE of decreased glucose levels (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">46.7 (37.9&#x02013;54.6)</td><td align="char" char=" " rowspan="1" colspan="1">53.8 (44.3&#x02013;87.3)</td><td align="char" char="." rowspan="1" colspan="1">0.0004</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean of daily difference (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">24.6 (16.4&#x02013;31.1)</td><td align="char" char=" " rowspan="1" colspan="1">25.2 (19.6&#x02013;39.0)</td><td align="char" char="." rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Average daily risk range</td><td align="char" char=" " rowspan="1" colspan="1">14.4 (9.0&#x02013;22.4)</td><td align="char" char=" " rowspan="1" colspan="1">17.3 (8.9&#x02013;24.5)</td><td align="char" char="." rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">24&#x02010;h mean glucose level (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">151.0 (128.1&#x02013;167.7)</td><td align="char" char=" " rowspan="1" colspan="1">153.4 (142.2&#x02013;192.4)</td><td align="char" char="." rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">00.00&#x02013;06.00 h mean glucose level (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">113.1 (93.4&#x02013;137.8)</td><td align="char" char=" " rowspan="1" colspan="1">132.1 (115.4&#x02013;168.8)</td><td align="char" char="." rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">08.00&#x02013;12.00 h mean glucose level (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">149.2 (126.9&#x02013;163.6)</td><td align="char" char=" " rowspan="1" colspan="1">150.3 (135.2&#x02013;166.8)</td><td align="char" char="." rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">12.00&#x02013;24.00 h mean glucose level (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">164.1 (137.9&#x02013;202.6)</td><td align="char" char=" " rowspan="1" colspan="1">166.8 (156.2&#x02013;211.0)</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">24&#x02010;h standard deviation (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">33.4 (27.2&#x02013;40.3)</td><td align="char" char=" " rowspan="1" colspan="1">33.5 (27.3&#x02013;55.0)</td><td align="char" char="." rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">00.00&#x02013;06.00 h SD (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">8.5 (6.1&#x02013;13.9)</td><td align="char" char=" " rowspan="1" colspan="1">10.8 (8.7&#x02013;18.4)</td><td align="char" char="." rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" rowspan="1" colspan="1">08.00&#x02013;12.00 h SD (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">20.3 (16.5&#x02013;26.5)</td><td align="char" char=" " rowspan="1" colspan="1">25.8 (18.0&#x02013;32.7)</td><td align="char" char="." rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">12.00&#x02013;24.00 h SD (mg/dL)</td><td align="char" char=" " rowspan="1" colspan="1">28.1 (21.5&#x02013;33.6)</td><td align="char" char=" " rowspan="1" colspan="1">30.4 (21.0&#x02013;38.8)</td><td align="char" char="." rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" colspan="4" rowspan="1">Preprandial glucose level (mg/dL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lunch &#x02212; breakfast</td><td align="char" char=" " rowspan="1" colspan="1">7.5 (&#x02212;10.5 to 29.3)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;4.0 (&#x02212;32.0 to 5.8)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="4" rowspan="1">Highest postprandial glucose level within 3 h after each meal (mg/dL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breakfast</td><td align="char" char=" " rowspan="1" colspan="1">173.5 (160.6&#x02013;192.8)</td><td align="char" char=" " rowspan="1" colspan="1">198.0 (165.8&#x02013;217.0)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lunch</td><td align="char" char=" " rowspan="1" colspan="1">193.5 (167.5&#x02013;232.5)</td><td align="char" char=" " rowspan="1" colspan="1">200.0 (173.8&#x02013;241.8)</td><td align="char" char="." rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Supper</td><td align="char" char=" " rowspan="1" colspan="1">212.8 (187.0&#x02013;251.0)</td><td align="char" char=" " rowspan="1" colspan="1">214.5 (198.0&#x02013;258.8)</td><td align="char" char="." rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" colspan="4" rowspan="1">Time from start of meal to the highest postprandial glucose level (min)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breakfast</td><td align="char" char=" " rowspan="1" colspan="1">75.0 (51.3&#x02013;98.8)</td><td align="char" char=" " rowspan="1" colspan="1">62.5 (50.0&#x02013;85.0)</td><td align="char" char="." rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lunch</td><td align="char" char=" " rowspan="1" colspan="1">97.5 (71.3&#x02013;158.8)</td><td align="char" char=" " rowspan="1" colspan="1">100.0 (70.0&#x02013;125.0)</td><td align="char" char="." rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Supper</td><td align="char" char=" " rowspan="1" colspan="1">102.5 (81.3&#x02013;140.0)</td><td align="char" char=" " rowspan="1" colspan="1">97.5 (71.3&#x02013;158.8)</td><td align="char" char="." rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" colspan="4" rowspan="1">Differences between preprandial and highest postprandial glucose level for each meal (mg/dL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breakfast</td><td align="char" char=" " rowspan="1" colspan="1">47.0 (29.5&#x02013;71.3)</td><td align="char" char=" " rowspan="1" colspan="1">66.0 (47.5&#x02013;95.5)</td><td align="char" char="." rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lunch</td><td align="char" char=" " rowspan="1" colspan="1">77.5 (47.3&#x02013;100.8)</td><td align="char" char=" " rowspan="1" colspan="1">76.0 (48.3&#x02013;104.8)</td><td align="char" char="." rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Supper</td><td align="char" char=" " rowspan="1" colspan="1">69.0 (33.8&#x02013;89.8)</td><td align="char" char=" " rowspan="1" colspan="1">61.5 (40.3&#x02013;101.0)</td><td align="char" char="." rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" colspan="4" rowspan="1">Postprandial glucose gradient (mg/dL min)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breakfast</td><td align="char" char=" " rowspan="1" colspan="1">0.73 (0.31&#x02013;1.11)</td><td align="char" char=" " rowspan="1" colspan="1">1.26 (0.66&#x02013;1.72)</td><td align="char" char="." rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lunch</td><td align="char" char=" " rowspan="1" colspan="1">0.68 (0.39&#x02013;1.01)</td><td align="char" char=" " rowspan="1" colspan="1">0.79 (0.52&#x02013;1.04)</td><td align="char" char="." rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Supper</td><td align="char" char=" " rowspan="1" colspan="1">0.55 (0.35&#x02013;1.05)</td><td align="char" char=" " rowspan="1" colspan="1">0.59 (0.36&#x02013;0.98)</td><td align="char" char="." rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" colspan="4" rowspan="1">AUC (&#x02265;180 mg/dL) within 3 h after each meal (mg min/dL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breakfast</td><td align="char" char=" " rowspan="1" colspan="1">0.0 (0.0&#x02013;828.1)</td><td align="char" char=" " rowspan="1" colspan="1">690.0 (0.0&#x02013;4,338.1)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lunch</td><td align="char" char=" " rowspan="1" colspan="1">180.6 (0.0&#x02013;5,804.1)</td><td align="char" char=" " rowspan="1" colspan="1">1,219.4 (0.0&#x02013;7,058.8)</td><td align="char" char="." rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Supper</td><td align="char" char=" " rowspan="1" colspan="1">4,009.4 (251.3&#x02013;13,306.9)</td><td align="char" char=" " rowspan="1" colspan="1">3,159.9 (343.1&#x02013;12,530.6)</td><td align="char" char="." rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">24&#x02010;h AUC, &#x02265;0 mg/dL (mg min/dL)</td><td align="char" char=" " rowspan="1" colspan="1">217,386.7 (184,660.1&#x02013;241,610.1)</td><td align="char" char=" " rowspan="1" colspan="1">220,806.8 (204,782.1&#x02013;277,096.4)</td><td align="char" char="." rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">24&#x02010;h AOC, &#x0003c;70 mg/dL (mg min/dL)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="char" char="." rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">00.00&#x02013;06.00 h AOC, &#x0003c;70 mg/dL (mg min/dL)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="char" char="." rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">08.00&#x02013;12.00 h AOC, &#x0003c;70 mg/dL (mg min/dL)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="char" char=" " rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="jdi12661-note-0003"><p>Data are shown as median (interquartile range). <italic>P</italic>, Wilcoxon signed&#x02010;rank test. AOC, area over the glucose curve; AUC, area under the glucose curve; MAGE, mean amplitude of glycemic excursion.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The difference in the highest post&#x02010;breakfast glucose levels between groups (&#x00394; = G + G300 &#x02212; L + GB) was significantly correlated to AUC in 24 h (<italic>r</italic> = 0.39, <italic>P</italic> = 0.03; Spearman's rank correlation coefficient).</p></sec></sec><sec id="jdi12661-sec-0012"><title>Discussion</title><p>The results of the present study suggest that the combination therapy of G + G300 decreases post&#x02010;breakfast glucose level reducing rate of rise of that, nocturnal and 24&#x02010;h glucose variability and level without causing hypoglycemia, and daily variance. Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref> shows a schematic diagram of the estimated insulin concentration in both G + G300 and L + GB, to investigate the basis of the results obtained from the present study.</p><fig fig-type="Figure" xml:lang="en" id="jdi12661-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The graph shows a schematic diagram of the estimated insulin concentration in glulisine + insulin glargine 300 U/mL and lispro + insulin glargine biosimilar. AUC (&#x02265;180), area under the glucose curve (&#x02265;180 mg/dL) within 3 h; Glargine 300 U/mL, insulin glargine 300 U/mL; Glargine biosimilar, insulin glargine biosimilar; Glulisine, insulin glulisine; Highest post&#x02010;breakfast glucose levels, highest post&#x02010;breakfast glucose level within 3 h; Increase post&#x02010;breakfast glucose levels, differences between pre&#x02010;breakfast and highest post&#x02010;breakfast glucose levels; Lispro, insulin lispro; MAGE+, mean amplitude of glycemic excursion of increased glucose levels; MAGE&#x02212;, mean amplitude of glycemic excursion of decreased glucose levels; MAGE, mean amplitude of glycemic excursion; MODD, mean of daily difference; SD, standard deviation.</p></caption><graphic id="nlm-graphic-5" xlink:href="JDI-9-91-g002"/></fig><p>The finding that the highest post&#x02010;breakfast glucose level, increased post&#x02010;breakfast glucose level, post&#x02010;breakfast glucose gradient and AUC (&#x02265;180 mg/dL) within 3 h after breakfast were significantly lower in patients taking G + G300 than those taking L + GB was thought to be caused by the difference of insulin concentration between glulisine and lispro (part 1 of Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref>) because of the rapid onset of action of glulisine. Namely, we believe that post&#x02010;breakfast glucose levels decreased with the reduced rate of rise, because glulisine was affected faster and stronger by the difference (part 1 of Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref>). In fact, it has been reported that time to 50% serum insulin concentration of glulisine was significantly earlier than that of lispro or insulin aspart.<xref rid="jdi12661-bib-0025" ref-type="ref">25</xref> The onset of glulisine's effect has been suggested to be faster than the other ultra&#x02010;rapid&#x02010;acting insulins, and this is supported by the results of the present study. The result that the difference in the highest post&#x02010;breakfast glucose level between groups (&#x00394; = G + G300 &#x02212; L + GB) was significantly correlated to AUC in 24 h, suggests that as well as reducing the highest post&#x02010;breakfast glucose levels, glulisine also produces a greater reduction in glucose levels measured over a 24&#x02010;h period. Conversely, the result that pre&#x02010;lunch &#x02212; pre&#x02010;breakfast glucose levels were significantly lower in patients taking L + GB than those taking G + G300 was thought to be due to the difference in serum insulin concentration between glulisine and lispro (part 2 of Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref>), because serum concentrations of glulisine reduce more rapidly than those of lispro. Namely, we believe that pre&#x02010;lunch glucose levels decreased too much, because lispro was affected too much by the difference of insulin concentration (part 2 of Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref>). It has been reported that the mean residence time of glulisine was approximately half of that of lispro or rapid&#x02010;acting insulin.<xref rid="jdi12661-bib-0026" ref-type="ref">26</xref> The wearing off of glulisine's effect has been suggested to be faster than lispro or rapid&#x02010;acting insulin, and this supports the present study results. Therefore, we believe that morning lispro administration might cause hypoglycemia before lunch, but morning glulisine administration can avoid the risk of hypoglycemia before lunch in patients with low pre&#x02010;breakfast glucose levels. We believe that the rapid onset and fast wearing off of glulisine's effect (Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref> [1] and Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref> [2]) led to the result that MAGE+, MAGE&#x02212; and MAGE were significantly lower in patients taking G + G300 than those taking L + GB, because those characteristics of glulisine's action reduced rapid increases and decreases of morning glucose levels. It has been reported that the concentration of protein kinase C&#x02010;&#x003b2;, which is an index of oxidative stress, increases when glucose concentration decreases; that is, from hyperglycemia status to normoglycemia status.<xref rid="jdi12661-bib-0027" ref-type="ref">27</xref> Therefore, it is significant that glulisine can reduce not only rapid increases, but also rapid decreases of glucose levels. The result that 00.00&#x02013;06.00 h M&#x02010;value and 00.00&#x02013;06.00 h SD were significantly lower in patients taking G + G300 than those taking L + GB was thought to be caused by the difference in serum insulin concentration between insulin glargine biosimilar (glargine BS) and glargine 300 U/mL between 00.00&#x02013;06.00 h (Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref>). The duration of action as a clinical effect of glargine BS was thought to be approximately 22.8 h.<xref rid="jdi12661-bib-0028" ref-type="ref">28</xref>, <xref rid="jdi12661-bib-0029" ref-type="ref">29</xref> In contrast, the duration of action as a clinical effect of glargine 300 U/mL was thought to be just 24 h.<xref rid="jdi12661-bib-0030" ref-type="ref">30</xref> Therefore, we believe that glargine 300 U/mL improves nocturnal glycemic variability more than glargine BS, because the serum concentration of glargine BS varies, but that of glargine 300 U/mL is stable between 00.00&#x02013;06.00 h (Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref>). The result that 00.00&#x02013;06.00 h mean glucose levels, AUC (&#x02265;0) in 24 h, 24&#x02010;h SD, 24&#x02010;h M&#x02010;value and MAGE were significantly lower in patients taking G + G300 than those taking L + GB was thought to be due to the fact that glargine 300 U/mL improves 24&#x02010;h glycemic variability with a focus on night&#x02010;time more than glargine BS<xref rid="jdi12661-bib-0030" ref-type="ref">30</xref> (Figure <xref rid="jdi12661-fig-0002" ref-type="fig">2</xref> [3]), and that glulisine improves 24&#x02010;h glycemic variability through improvement of pre&#x02010; and post&#x02010;breakfast glycemic variability more than lispro,<xref rid="jdi12661-bib-0014" ref-type="ref">14</xref> namely, the combination therapy of glargine 300 U/mL and glulisine. The result that MODD was significantly lower in patients taking G + G300 than those taking L + GB was thought to be caused by the small variance in daily effect of glargine 300 U/mL. Day&#x02010;to&#x02010;day variability (coefficient of variation %) in the area under the curve of glucose infusion rate over 24 h of glargine BS is 73%.<xref rid="jdi12661-bib-0029" ref-type="ref">29</xref>, <xref rid="jdi12661-bib-0031" ref-type="ref">31</xref> In contrast, that of glargine 300 U/mL is 34.8%.<xref rid="jdi12661-bib-0032" ref-type="ref">32</xref> Daily variance of glargine 300 U/mL is much smaller than that of glargine BS, and this supports the present study results. Regarding daily variance, it has been suggested that larger daily variance of glycosylated hemoglobin and glucose levels causes a higher incidence of cardiovascular events and is associated with a poor prognosis.<xref rid="jdi12661-bib-0033" ref-type="ref">33</xref> Daily stability of the glargine 300 U/mL effect is thought to improve cardiovascular events and prognosis.</p><p>In the present study, it was suggested that nocturnal glucose level was significantly lower in patients taking G + G300 than those taking L + GB. Decreasing nocturnal glucose levels might be interpreted as increasing the potential risk of hypoglycemia. However, at the same time, nocturnal glycemic variability was significantly lower in patients taking G + G300 than those taking L + GB in the present study. We believe that reducing glucose levels with decreasing variability does not increase the potential risk of hypoglycemia. In the present study, hypoglycemia was not significantly different between groups.</p><p>From the viewpoint of diabetes education, the practice of not eating breakfast in order to decrease post&#x02010;breakfast glucose levels might exist amongst the diabetic population. However, it has been reported that the incidence of diabetes is significantly increased in people who miss breakfast than in those who eat breakfast.<xref rid="jdi12661-bib-0034" ref-type="ref">34</xref> Missing breakfast is thought to cause worsening of glycemic control. In a clinical trial that provides detailed support for this theory, it has been reported that post&#x02010;lunch and supper glucose levels increase more in patients missing breakfast than in those eating breakfast.<xref rid="jdi12661-bib-0035" ref-type="ref">35</xref> In addition, the second meal effect that increased post&#x02010;lunch glucose levels was lower than the increased post&#x02010;breakfast glucose levels that have been reported.<xref rid="jdi12661-bib-0011" ref-type="ref">11</xref> Post&#x02010;lunch glucose levels increase more in patients skipping breakfast than those taking breakfast. High serum concentration of free fatty acids reduces insulin sensitivity. Free fatty acids levels are reduced to a greater extent before lunch than before breakfast by eating breakfast, and this causes the second meal effect. Post&#x02010;lunch glucose levels increase in patients missing breakfast, because free fatty acids levels do not decrease, and thus insulin sensitivity does not improve. Therefore, missing breakfast causes an increase in post&#x02010;lunch and supper glucose levels, and worsening of glycemic control. Patients should eat breakfast, and post&#x02010;breakfast glucose levels should be reduced by medication.</p><p>An advantage of the combination therapy of glargine 300 U/mL and glulisine considered from the viewpoint of diabetes education is that the injection is only given in the morning. In this regard, this combination therapy is almost the same as basal insulin therapy, and significant hypoglycemic actions can be expected as a result of adding glulisine. Another combination therapy consisting of basal insulin + glucagon&#x02010;like peptide&#x02010;1 receptor agonist (GLP&#x02010;1 RA) exists. However, GLP&#x02010;1 RA is costly, and its digestive side&#x02010;effects should be considered. Furthermore, goals of treatment are different between insulin and GLP&#x02010;1 RA. Therefore, combination therapy of basal insulin and GLP&#x02010;1 RA should be considered as being fundamentally different from combination therapy of morning long&#x02010;acting insulin and ultra&#x02010;rapid&#x02010;acting insulin. Combination long&#x02010;acting and ultra&#x02010;rapid&#x02010;acting insulin given as a single morning injection might be more desirable to patients, as it is easier to build into a daily routine, in a similar way to the habit of teeth&#x02010;brushing, for example, and is thus less likely to be forgotten or delayed. Understandably, patients might not enjoy injecting insulin, and so administering this necessary treatment at the start of the day could feasibly improve the quality of life for the diabetes patient. Additionally, given the importance of eating breakfast in the diabetic population, morning administration of insulin might help those who would previously have missed breakfast to remember to eat at this time, by linking the treatment with eating as part of the patient's daily routine.</p><p>In the present study, it was suggested that the combination therapy of glulisine + glargine 300 U/mL decreases post&#x02010;breakfast glucose level reducing rate of rise of that, nocturnal and 24&#x02010;h glucose variability and levels without causing hypoglycemia, and daily variance. As an insulin therapy that is injected in the morning only, the combination therapy of glulisine + glargine 300 U/mL is suggested to be the best therapy not only to improve glycemic variability, but also from a patient preference viewpoint. Thus, the clinical significance of the present study is high. However, this study had limitations as a single facility, open&#x02010;label study. We shall endeavor to address these limitations by gathering more cases and carrying out further clinical studies in the future.</p></sec><sec id="jdi12661-sec-0014"><title>Disclosure</title><p>The authors declare no conflict of interest.</p></sec></body><back><ack id="jdi12661-sec-0013"><title>Acknowledgments</title><p>This work was supported in part by the General Inuyamachuo Hospital.</p></ack><ref-list content-type="cited-references" id="jdi12661-bibl-0001"><title>References</title><ref id="jdi12661-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jdi12661-cit-0001">
<string-name>
<surname>Tsujimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamamoto&#x02010;Honda</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kajio</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>217</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">23939540</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jdi12661-cit-0002">
<string-name>
<surname>Bolli</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Perriello</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fanelli</surname>
<given-names>CG</given-names>
</string-name>, <italic>et al</italic>
<article-title>Nocturnal blood glucose control in type I diabetes mellitus</article-title>. <source>Diabetes Care</source>
<year>1993</year>; <volume>16</volume>: <fpage>71</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">8299480</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jdi12661-cit-0003">
<string-name>
<surname>Currie</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tynan</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study</article-title>. <source>Lancet</source>
<year>2010</year>; <volume>375</volume>: <fpage>481</fpage>&#x02013;<lpage>489</lpage>.<pub-id pub-id-type="pmid">20110121</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jdi12661-cit-0004">
<string-name>
<surname>Mendez</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Mok</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Ata</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>4091</fpage>&#x02013;<lpage>4097</lpage>.<pub-id pub-id-type="pmid">24170754</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jdi12661-cit-0005">
<string-name>
<surname>Takeishi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hachiya</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic>
<article-title>Hypoglycemia and glycemic variability are associated with mortality in non&#x02010;intensive care unit hospitalized infectious disease patients with diabetes mellitus</article-title>. <source>J Diabetes Investig</source>
<year>2016</year>; <volume>7</volume>: <fpage>429</fpage>&#x02013;<lpage>435</lpage>.</mixed-citation></ref><ref id="jdi12661-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jdi12661-cit-0006">
<string-name>
<surname>Takeishi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kawai</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Major Increases between Pre&#x02010; and Post&#x02010;breakfast Glucose Levels May Predict Nocturnal Hypoglycemia in Type 2 Diabetes</article-title>. <source>Intern Med</source>
<year>2016</year>; <volume>55</volume>: <fpage>2933</fpage>&#x02013;<lpage>2938</lpage>.<pub-id pub-id-type="pmid">27746428</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jdi12661-cit-0007">
<string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Atsumi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Asahina</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects</article-title>. <source>Diabetes Care</source>
<year>1998</year>; <volume>21</volume>: <fpage>1133</fpage>&#x02013;<lpage>1137</lpage>.<pub-id pub-id-type="pmid">9653608</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jdi12661-cit-0008">
<collab collab-type="authors">Guideline of American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes&#x02013;2015: summary of revisions</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>S4</fpage>.</mixed-citation></ref><ref id="jdi12661-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jdi12661-cit-0009">
<string-name>
<surname>Terauchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Koyama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>X</given-names>
</string-name>, <italic>et al</italic>
<article-title>New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)</article-title>. <source>Diabetes Obes Metab</source>
<year>2016</year>; <volume>18</volume>: <fpage>366</fpage>&#x02013;<lpage>374</lpage>.<pub-id pub-id-type="pmid">26662838</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jdi12661-cit-0010">
<string-name>
<surname>Ando</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tsujino</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>24&#x02010;hour glycemic variations in drug&#x02010;na&#x000ef;ve patients with type 2 diabetes: a continuous glucose monitoring (CGM)&#x02010;based study</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <fpage>e71102</fpage>.<pub-id pub-id-type="pmid">23936258</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jdi12661-cit-0011">
<string-name>
<surname>Jovanovic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gerrard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>R</given-names>
</string-name>. <article-title>The second&#x02010;meal phenomenon in type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2009</year>; <volume>32</volume>: <fpage>1199</fpage>&#x02013;<lpage>1201</lpage>.<pub-id pub-id-type="pmid">19366973</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jdi12661-cit-0012">
<string-name>
<surname>Monnier</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Colette</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sardinoux</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age</article-title>. <source>Diabetes Care</source>
<year>2012</year>; <volume>35</volume>: <fpage>2597</fpage>&#x02013;<lpage>2599</lpage>.<pub-id pub-id-type="pmid">22991448</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jdi12661-cit-0013">
<string-name>
<surname>Takeishi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kawai</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Investigating the relationship between morning glycemic variability and patient characteristics using continuous glucose monitoring data in patients with Type 2 Diabetes</article-title>. <source>Intern Med</source>
<year>2016</year> (Accepted).</mixed-citation></ref><ref id="jdi12661-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jdi12661-cit-0014">
<string-name>
<surname>Urakami</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kuwabara</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Habu</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficacy and safety of switching to insulin glulisine from other rapid&#x02010;acting insulin analogs in children with type 1 diabetes</article-title>. <source>J Diabetes Investig</source>
<year>2015</year>; <volume>6</volume>: <fpage>87</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="jdi12661-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jdi12661-cit-0015">
<string-name>
<surname>Morishita</surname>
<given-names>N</given-names>
</string-name>. <article-title>Efficacy and safety of insulin glulisine in patients with insufficiently controlled Type1 and Type2 diabetes</article-title>. <source>J New Rem &#x00026; Clin</source>
<year>2013</year>; <volume>62</volume>: <fpage>73</fpage>&#x02013;<lpage>79</lpage>.</mixed-citation></ref><ref id="jdi12661-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jdi12661-cit-0016">
<string-name>
<surname>Mori</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ohta</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shiozaki</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>The effect of a low&#x02010;carbohydrate/high&#x02010;monounsaturated fatty acid liquid diet and an isoleucine&#x02010;containing liquid diet on 24&#x02010;h glycemic variability in diabetes patients on tube feeding: a comparison by continuous glucose monitoring</article-title>. <source>Diabetes Technol Ther</source>
<year>2012</year>; <volume>14</volume>: <fpage>619</fpage>&#x02013;<lpage>623</lpage>.<pub-id pub-id-type="pmid">22540521</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jdi12661-cit-0017">
<string-name>
<surname>Service</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Molnar</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Rosevear</surname>
<given-names>JW</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mean amplitude of glycemic excursion, a measure of diabetic instability</article-title>. <source>Diabetes</source>
<year>1970</year>; <volume>19</volume>: <fpage>644</fpage>&#x02013;<lpage>655</lpage>.<pub-id pub-id-type="pmid">5469118</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jdi12661-cit-0018">
<collab collab-type="authors">Service FJ, Nelson RL</collab>
. <article-title>Characteristics of glycemic stability</article-title>. <source>Diabetes Care</source>
<year>1980</year>; <volume>3</volume>: <fpage>58</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">6996969</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jdi12661-cit-0019">
<string-name>
<surname>Kovatchev</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Otto</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>Evaluation of a new measure of blood glucose variability in diabetes</article-title>. <source>Diabetes Care</source>
<year>2006</year>; <volume>29</volume>: <fpage>2433</fpage>&#x02013;<lpage>2438</lpage>.<pub-id pub-id-type="pmid">17065680</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jdi12661-cit-0020">
<string-name>
<surname>Nishimura</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tsujino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Taki</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: a comparative pilot study &#x02010;results from the Jikei&#x02010;EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J&#x02010;EVOLVE) study</article-title>. <source>Cardiovasc Diabetol</source>
<year>2010</year>; <volume>9</volume>: <fpage>16</fpage>.<pub-id pub-id-type="pmid">20438630</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jdi12661-cit-0021">
<string-name>
<surname>Schlichtkrull</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Munck</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jersild</surname>
<given-names>M</given-names>
</string-name>. <article-title>The M&#x02010;valve, an index of blood&#x02010;sugar control in diabetics</article-title>. <source>Acta Med Scand</source>
<year>1965</year>; <volume>177</volume>: <fpage>95</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">14251860</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jdi12661-cit-0022">
<collab collab-type="authors">Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group</collab>
. <article-title>Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF&#x02010;CGM) trial</article-title>. <source>Diabetes Care</source>
<year>2010</year>; <volume>33</volume>: <fpage>17</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">19837791</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jdi12661-cit-0023">
<string-name>
<surname>Tanaka</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hiura</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Effects of rapid&#x02010;acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes</article-title>. <source>Endocrine J</source>
<year>2015</year>; <volume>62</volume>: <fpage>411</fpage>&#x02013;<lpage>416</lpage>.<pub-id pub-id-type="pmid">25739586</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jdi12661-cit-0024">
<string-name>
<surname>Sakamoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Irako</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J&#x02010;VICTORIA study)</article-title>. <source>Cardiovasc Diabetol</source>
<year>2012</year>; <volume>11</volume>: <fpage>92</fpage>.<pub-id pub-id-type="pmid">22867630</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jdi12661-cit-0025">
<string-name>
<surname>Morrow</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Muchmore</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Hompesch</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Comparative pharmacokinetics and insulin action for three rapid&#x02010;acting insulin analogs injected subcutaneously with and without hyaluronidase</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>273</fpage>&#x02013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">23043164</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="jdi12661-cit-0026">
<article-title>Common Technical Document</article-title>, 2. Clinical Overview, Apidra, Sanofi K.K.</mixed-citation></ref><ref id="jdi12661-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jdi12661-cit-0027">
<string-name>
<surname>Quagliaro</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Piconi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Assaloni</surname>
<given-names>R</given-names>
</string-name>, <italic>et al</italic>
<article-title>Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H&#x02010;oxidase activation</article-title>. <source>Diabetes</source>
<year>2003</year>; <volume>52</volume>: <fpage>2795</fpage>&#x02013;<lpage>2804</lpage>.<pub-id pub-id-type="pmid">14578299</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jdi12661-cit-0028">
<string-name>
<surname>Poon</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>AB</given-names>
</string-name>. <article-title>Glargine and detemir: safety and efficacy profiles of the long&#x02010;acting basal insulin analogs</article-title>. <source>Drug Healthc Patient Saf</source>
<year>2010</year>; <volume>2</volume>: <fpage>213</fpage>&#x02013;<lpage>223</lpage>.<pub-id pub-id-type="pmid">21701633</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jdi12661-cit-0029">
<string-name>
<surname>Linnebjerg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Seger</surname>
<given-names>ME</given-names>
</string-name>, <italic>et al</italic>
<article-title>Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU&#x02010; and US&#x02010;approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>2226</fpage>&#x02013;<lpage>2233</lpage>.<pub-id pub-id-type="pmid">26307603</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jdi12661-cit-0030">
<string-name>
<surname>Monnier</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Owens</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Bolli</surname>
<given-names>GB</given-names>
</string-name>. <article-title>The new long&#x02010;acting insulin glargine U300 achieves an early steady state with low risk of accumulation</article-title>. <source>Diabetes Metab</source>
<year>2016</year>; <volume>42</volume>: <fpage>77</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">26688145</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jdi12661-cit-0031">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hermanski</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady&#x02010;state conditions in type 1 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2012</year>; <volume>14</volume>: <fpage>859</fpage>&#x02013;<lpage>864</lpage>.<pub-id pub-id-type="pmid">22594461</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jdi12661-cit-0032">
<string-name>
<surname>Becker</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Nowotny</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Teichert</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>Low within&#x02010; and between&#x02010;day variability in exposure to new insulin glargine 300 U/mL</article-title>. <source>Diabetes Obes Metab</source>
<year>2015</year>; <volume>7</volume>: <fpage>261</fpage>&#x02013;<lpage>267</lpage>.</mixed-citation></ref><ref id="jdi12661-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jdi12661-cit-0033">
<string-name>
<surname>Hirakawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Arima</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zoungas</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Impact of visit&#x02010;to&#x02010;visit glycemic variability on the risks of macrovascular and microvascular events and all&#x02010;cause mortality in type 2 diabetes: the ADVANCE trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2359</fpage>&#x02013;<lpage>2365</lpage>.<pub-id pub-id-type="pmid">24812434</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jdi12661-cit-0034">
<string-name>
<surname>Uemura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yatsuya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hilawe</surname>
<given-names>EH</given-names>
</string-name>, <italic>et al</italic>
<article-title>Breakfast skipping is positively associated with incidence of type 2 diabetes mellitus: evidence from the Aichi Workers&#x02019; Cohort Study</article-title>. <source>J Epidemiol</source>
<year>2015</year>; <volume>25</volume>: <fpage>351</fpage>&#x02013;<lpage>358</lpage>.<pub-id pub-id-type="pmid">25787236</pub-id></mixed-citation></ref><ref id="jdi12661-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jdi12661-cit-0035">
<string-name>
<surname>Jakubowicz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wainstein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>, <italic>et al</italic>
<article-title>Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>1820</fpage>&#x02013;<lpage>1826</lpage>.<pub-id pub-id-type="pmid">26220945</pub-id></mixed-citation></ref></ref-list></back></article>